StockData
ICU Medical Inc logo

ICU Medical Inc (ICUI) company profile

ICUINasdaqSurgical & Medical Instruments & ApparatusFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 5, 2026Score 9/3034% above fair value
$179.27+1.97 (+1.11%)

Close on Nov 13, 2026Market cap $4.48BP/E 74.4Yield –

About ICU Medical

Surgical & Medical Instruments & Apparatus, SIC 3841

ICU Medical, Inc. develops, manufactures, and sells medical devices and products used in infusion therapy, vascular access, and vital care settings. The company operates through business units that include Consumables, Infusion Systems, and Vital Care. Its offerings encompass ambulatory, syringe, and large volume infusion pumps, safety software, dedicated and non-dedicated IV sets, needlefree connectors, vascular access catheters, closed system transfer devices, tracheostomy tubes, temperature management systems, hemodynamic monitoring devices, and regional anesthesia products. ICU Medical provides these solutions primarily to acute care hospitals, wholesalers, ambulatory clinics, and alternate site care facilities, including outpatient centers and long-term care providers.

The company distributes its products globally, serving customers in more than 100 countries through a direct sales team and independent distributors. ICU Medical operates manufacturing facilities in the United States, Costa Rica, Mexico, and the Czech Republic, and maintains device service centers across several countries, including Germany, Canada, Taiwan, and Australia. Its corporate headquarters are located in San Clemente, California.

Summary of the business section of ICU Medical's latest annual report, written by StockData.

Company profile

Company

Legal name
ICU Medical Inc
Founded
1984
Headquarters
San Clemente, CA
Address
951 Calle Amanecer 92763-6212
Phone
(949) 366-2183
Employees
13,000, Dec 31, 2025
Industry
Surgical & Medical Instruments & Apparatus
Incorporated in
Delaware
Fiscal year ends
December 31
Auditor
DELOITTE & TOUCHE LLP, Costa Mesa, California

Stock & identifiers

Ticker
ICUI
Exchange
Nasdaq
IPO date
Mar 31, 1992
Shares outstanding
25M, Jul 31, 2026
Public float
$3.23B, Jun 30, 2025
Filer category
Large accelerated filer
Stock splits
3-for-2, Mar 18, 2002; 3-for-2, Apr 1, 1993
SEC CIK
883984
CUSIP
44930G107
ISIN
US44930G1076
FIGI
BBG000CQV2N4
Share class FIGI
BBG001S712B3
LEI
5493003NRW7LS2QZRH60
EIN
33-0022692

Executives and directors

Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years

NamePositionShares owned
Vivek JainChairman and CEO, Director276,993
Virginia Ruth SanzoneVP, General Counsel16,020
Brian Michael BonnellChief Financial Officer56,062
Daniel WoolsonVP, GM-Infusion Capital17,062
Ben SousaChief Information Officer3,076
Christian B. VoigtlanderChief Operating Officer37,377
Elisha W. FinneyDirector4,871
David F. HoffmeisterDirector6,004
David C. GreenbergDirector9,714
Donald AbbeyDirector6,004
Laurie HernandezDirector4,862
Kolleen T. KennedyDirector4,539

CEO pay and shareholder return

Pay versus performance table from the proxy statement

Fiscal yearCEO total payCEO pay actually paidOther executives (avg)Value of $100 investedPeer group
FY2025$6.45M$9.20M$3.20M$67$68
FY2024$6.45M$23.09M$3.25M$83$96
FY2023$6.81M-$8.07M$3.37M$53$106
FY2022$5.66M-$11.28M$2.79M$84$100
FY2021$5.07M$13.34M$2.65M$127$152
FY2020$3.31M$14.34M$1.56M$115$127

“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.

Executive compensation, fiscal 2025

Summary compensation table from the latest proxy statement

ExecutiveSalaryStock awardsIncentive payOtherTotalvs. prior year
Vivek Jain
Chairman of the Board and Chief Executive Officer
$775.00K$4.50M$1.16M$14.52K$6.45M-0%
Brian Bonnell
Chief Financial Officer
$475.00K$3.00M$427.50K–$3.90M-2%
Christian Voigtlander
Chief Operating Officer
$500.00K$3.00M$450.00K–$3.95M-2%
Daniel Woolson
Corporate Vice President, General Manager - Infusion Systems
$395.19K$1.35M$360.00K$11.50K$2.12M+2%
Virginia Sanzone
Corporate Vice President, General Counsel
$430.00K$2.00M$387.00K–$2.82M-3%

Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.

Employees

Headcount reported in annual reports

“At December 31, 2025, we had approximately 13,000 employees located in over 35 countries.”

Corporate history

Events identified from SEC filings

See a number that looks wrong?